SCHEMBL29889342

SCHEMBL29889342

COc1ccc(-c2cccc(F)c2)c2nc(NC(=O)N3CCC(C)(O)CC3)[nH]c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 2/20 0.44
▸ HCRTR2 O43614 2/20 0.44
▸ CYP2D6 P10635 4/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ ADORA3 P0DMS8 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ ALDH1A1 P00352 6/20 0.41
▸ CYP3A4 P08684 4/20 0.41
▸ USP2 O75604 3/20 0.41
▸ TSHR P16473 2/20 0.41
▸ CSNK1E P49674 1/20 0.39
▸ CCNT1 O60563 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ NPY5R Q15761 1/20 0.38
▸ ABCB1 P08183 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20765632 1.00 HCRTR1 (0.44) HCRTR1HCRTR2CYP2D6CYP2C19CYP1A2
SCHEMBL29890474 0.90 ADORA2A (0.43) HCRTR1HCRTR2ADORA3ADORA2AADORA2B
SCHEMBL20765052 0.90 ADORA2A (0.43) HCRTR1HCRTR2ADORA3ADORA2AADORA2B
SCHEMBL29889767 0.89 ADORA2A (0.45) CYP2D6CYP2C19CYP1A2ADORA3ADORA2A
SCHEMBL29889382 0.86 ADORA2A (0.45) CYP2C19CYP1A2ADORA3ADORA2AADORA2B
SCHEMBL20765033 0.86 ADORA2A (0.45) CYP2C19CYP1A2ADORA3ADORA2AADORA2B
SCHEMBL20765623 0.85 ADORA2A (0.43) HCRTR1HCRTR2CYP2C19ADORA3ADORA2A
SCHEMBL29889344 0.85 ADORA2A (0.43) HCRTR1HCRTR2CYP2C19ADORA3ADORA2A
SCHEMBL20765074 0.85 ADORA2A (0.41) ADORA3ADORA2AADORA2BADORA1
SCHEMBL29889480 0.85 ADORA2A (0.41) ADORA3ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-09-29 — — US disclosed
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2022-09-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 HCRTR1 2139/4885HCRTR2 2572/4885CYP2D6 1990/4885
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 HCRTR1 2178/4885HCRTR2 2680/4885CYP2D6 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback